Technical Analysis for RGNX - REGENXBIO Inc.

Grade Last Price % Change Price Change
C 19.78 0.82% 0.16
RGNX closed up 0.82 percent on Wednesday, December 6, 2023, on 49 percent of normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
Multiple of Ten Bearish Other 0.00%
NR7 Range Contraction 0.82%
Narrow Range Bar Range Contraction 0.82%
Inside Day Range Contraction 0.82%
Multiple of Ten Bullish Other -1.15%
Up 3 Days in a Row Strength -1.15%
1,2,3 Pullback Bullish Bullish Swing Setup 0.56%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.56%
Inside Day Range Contraction 0.56%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High about 23 hours ago
Up 2% about 23 hours ago
Up 1% about 24 hours ago
Possible NR7 2 days ago
Possible Inside Day 2 days ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


REGENXBIO Inc. Description

REGENXBIO Inc., a biotechnology company, focuses on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company's development programs include RGX-501, a product candidate for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111, a product candidate for the treatment of Mucopolysaccharidosis Type I, which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system. Its programs also include RGX-121, a product candidate for the treatment of Mucopolysaccharidosis Type II; RGX-314, a product candidate for the treatment of wet age-related macular degeneration; and RGX-321, a product candidate for the treatment of X-linked retinitis pigmentosa. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Emerging Technologies Molecular Biology Gene Therapy Genetics Medical Genetics Macular Degeneration Applied Genetics Cholesterol Gene Delivery Wet Age Related Macular Degeneration Lipoprotein Hypercholesterolemia Retinitis Adeno Associated Virus Mucopolysaccharidosis Retinitis Pigmentosa Homozygous Familial Hypercholesterolemia Iduronidase Rgx

Is RGNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 25.54
52 Week Low 12.82
Average Volume 455,211
200-Day Moving Average 18.65
50-Day Moving Average 17.06
20-Day Moving Average 18.98
10-Day Moving Average 19.43
Average True Range 0.86
RSI (14) 61.83
ADX 34.63
+DI 29.15
-DI 11.42
Chandelier Exit (Long, 3 ATRs) 18.29
Chandelier Exit (Short, 3 ATRs) 17.59
Upper Bollinger Bands 20.97
Lower Bollinger Band 16.99
Percent B (%b) 0.7
BandWidth 20.98
MACD Line 0.83
MACD Signal Line 0.83
MACD Histogram -0.0048
Fundamentals Value
Market Cap 739.94 Million
Num Shares 37.4 Million
EPS -1.36
Price-to-Earnings (P/E) Ratio -14.55
Price-to-Sales 9.50
Price-to-Book 3.33
PEG Ratio 0.26
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.57
Resistance 3 (R3) 20.60 20.37 20.44
Resistance 2 (R2) 20.37 20.17 20.35 20.39
Resistance 1 (R1) 20.07 20.04 19.96 20.04 20.35
Pivot Point 19.84 19.84 19.78 19.83 19.84
Support 1 (S1) 19.55 19.64 19.43 19.52 19.21
Support 2 (S2) 19.32 19.52 19.30 19.17
Support 3 (S3) 19.02 19.32 19.12
Support 4 (S4) 18.99